Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03), Zacks reports.
Mereo BioPharma Group Stock Up 1.7 %
Shares of NASDAQ:MREO opened at $2.41 on Friday. The stock’s 50-day moving average price is $2.73 and its 200-day moving average price is $3.51. Mereo BioPharma Group has a 12-month low of $2.22 and a 12-month high of $5.02.
Analyst Ratings Changes
A number of research analysts recently weighed in on MREO shares. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a report on Thursday. They issued an “overweight” rating and a $7.00 price target on the stock. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Mereo BioPharma Group in a research report on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.71.
Mereo BioPharma Group Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
See Also
- Five stocks we like better than Mereo BioPharma Group
- What is the S&P 500 and How It is Distinct from Other Indexes
- Archer Aviation Stock Sees Surge in Institutional Buys
- Profitably Trade Stocks at 52-Week Highs
- These 4 Stocks Offer High Upside in the AI Data Center Boom
- Comparing and Trading High PE Ratio Stocks
- How Can Tomahawk 6 Contribute to Broadcom’s AI Growth Story?
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
